veryone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals or companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.


Sanofi: If the company ever develops a Zika virus vaccine, it may get to charge whatever wants. The drug maker rejected a request from the US Army that any vaccine would cost Americans no more than folks in any other well-to-do country. Lawmakers, led by Senator Bernie Sanders, argue the Army should insist on fair pricing because Sanofi may win exclusive rights to the patents, which were developed with American taxpayer dollars. Of course, this may amount to much ado about nothing if Zika becomes less of a priority, but the larger issue in play is the extent to which drug makers may benefit from selling products that were developed with taxpayer funds.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy